Comtan (entacapone) / Orion Corp, Alvogen, Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Comtan (entacapone) / Novartis, Orion Corp
NCT02834507: Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients

Completed
2
19
Europe
Placebo, BIA 3-202, Nebicapone, Comtan®, Entacapone, Sinemet®, levodopa/carbidopa
Bial - Portela C S.A.
Parkinson's Disease (PD)
11/05
11/05
NCT00237263: An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States

Completed
2
285
US
Entacapone
Novartis
Parkinson's Disease
07/07
07/07
NCT03103399: Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon

Completed
2
254
NA
Comtan®, entacapone, Nebicapone, BIA 3-202, Levodopa/DDCI, Levodopa plus a dopa decarboxylase inhibitor (DDCI: carbidopa or benserazide), Placebo, placebo tablets
Bial - Portela C S.A.
Parkinson Disease
09/07
09/07
2006-001793-24: A MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED TRIAL TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF NEBICAPONE IN PARKINSON’S DISEASE PATIENTS WITH “WEARING-OFF” PHENOMENON TREATED WITH LEVODOPA/CARBIDOPA OR LEVODOPA/BENSERAZIDE

Completed
2
15
Europe
Nebicapone, Entacapone, BIA 3-202, COMTAN®, COMTAN®
BIAL - Portela & Cª, SA
Patients with idiopathic Parkinson’s disease (PD) and with end-of-dose deterioration (\"wearing-off\") phenomenon although currently treated with levodopa/DDCI.
 
09/07
NCT00491998 / 2006-004112-51: PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets

Completed
1/2
27
Europe
V1512, V1512 and Entacapone
Vernalis (R&D) Ltd, Cita NeuroPharmaceuticals, Syneos Health
Parkinson's Disease
11/07
11/07
NCT02349243: Effect of Entacapone on Bodyweight Loss in Obese Population

Unknown status
1/2
30
RoW
Entacapone, Comtan, Placebo, Sugar pills manufactured to mimic entacapone 200mg tablet
Kaichun Wu, National Institute of Biological Sciences, Beijing
Obesity
09/15
11/15
NCT00262470: Treatment of Orthostatic Intolerance

Active, not recruiting
1/2
150
US
Acetazolamide, Diamox, Atomoxetine, Strattera, NO Drug, Clonidine, Catapres, Entacapone, Comtan, Entacapone & Propranolol, Inderal, Atomoxetine & Propranolol, Indomethacin, Indocin, Mecamylamine, inversine, Isosorbide Dinitrate, Isordil, Melatonin, Midodrine, pro-amatine, Modafinil, provigil, Octreotide, sandostatin, Placebo, Propranolol, Modafinil & Propranolol, Provigil, Sertraline, Zoloft, IV Saline, NaCl solution (0.9%), Drinking Water, Breathing Device, memantine, Namenda, Abdominal binder
Satish R. Raj, National Center for Advancing Translational Sciences (NCATS)
Tachycardia, Chronic Orthostatic Intolerance
12/25
12/25

Download Options